CYPHERPUNK TECHNOLOGIES INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$65.00 thousand for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-12.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-05-12
- CYPHERPUNK TECHNOLOGIES INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$65.00K.
- CYPHERPUNK TECHNOLOGIES INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-03-31 was -$30.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month |
|---|---|
| 2017-03-31 | -$65.00K 10-Q · filed 2017-05-12 |
| 2016-03-31 | -$30.00K 10-Q · filed 2017-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |